British catalyst technologies firm Reaxa has slashed the prices of
its encapsulated catalysts by two-thirds following increased demand
for production scale quantities in pharma applications.
Catalyst company Chiral Quest has launched a new product,
C3-TunePhos, designed for use in the synthesis of a range of drugs,
including the cholesterol-lowering statin class.
Welsh company Great Lakes Fine Chemicals has teamed up with Phoenix
Chemicals to develop new, more cost effective processes for the
production of pharmaceutical intermediates.
A new ligand for use in the production of chiral pharmaceutical
intermediates, developed by France's Synkem, promises improved
performance over rival products.
Billion dollar science and technology company Dowpharma, a business
unit of The Dow Chemical company, has announced new capabilities in
catalytic asymmetric hydroformylation (AHF) of olefins for
applications in the development and...